当归多糖联合阿糖胞苷诱导人白血病KG1α细胞株衰老的实验研究

Experimental study on aging effect of Angelica sinensis polysaccharides combined with cytarabine on human leukemia KG1α cell lines

作者实验室最新研究发现,当归多糖(Angelica sinensis polysaccharides,ASP)对延缓造血干细胞衰老有明确的调控作用。白血病是一种造血干细胞水平的恶性血液肿瘤,ASP对白血病细胞有无调控衰老的作用却未见相关报道。该研究以对数生长期人急性髓系白血病(acute myeloid leukemia,AML)细胞株KG1α为研究对象,将其分为当归多糖组(ASP组),阿糖胞苷组(Ara-C组),当归多糖与阿糖胞苷联合组(ASP+Ara-C组)和对照组,分别加入不同浓度的ASP,Ara-C和ASP+Ara-C,作用不同时间,旨在研究当归多糖联合阿糖胞苷诱导人白血病细胞株KG1α衰老的作用及其相关机制。结果显示,ASP,AraC,ASP+Ara-C在体外能明显抑制KG1α细胞增殖,使细胞阻滞于G0/G1期;细胞呈现衰老形态学特点;衰老染色阳性细胞率显著增高;并能显著上调衰老相关蛋白P16与RB的表达,ASP+Ara-C组的上述指标更加显著。综上所述,ASP与Ara-C诱导KG1α细胞衰老的机制可能与调控衰老相关蛋白的表达有关,提示ASP与抗肿瘤药物联合用药在白血病治疗中可起到更好作用。

The latest findings of our laboratory showed that Angelica sinensis polysaccharide （ASP） showed a definite effect in regulating the aging of hematopoietic stem cells. Leukemia is a type of malignant hematopoietic tumor in hematopoietic stem cells. There have been no relevant reports about ASP＇s effect in regulating the aging of leukemia cells. In this study, human acute myeloid leukemia （AML） KG1α cell lines in logarithmic growth phase were taken as the study object, and were divided into the ASP group, the cytarabine （Ara-C） group, the ASP ＋Ara-C group and the control group. The groups were respectively treated with different concentration of ASP, Ara-C and ASP＋Ara-C for different periods, with the aim to study the effect of ASP combined with Ara-C in regulating the aging of human acute myeloid leukemia KG1α cell lines and its relevant mechanism. The results showed that ASP, Ara-C and ASP＋Ara-C could obviously inhibit KG1α cell proliferation in vitro, block the cells in G0/G1 phase. The cells showed the aging morphological feature. The percentage of positive stained aging cells was dramatically increased, and could significantly up-regulate the expression of aging-related proteins P16 and RB, which were more obvious in the ASP＋Ara-C group. In conclusion, the aging mechanism of KG1α cell induced by ASP and Ara-C may be related to the regulation of the expression of aging-related proteins, suggesting that the combined administration of ASP and anticancer drugs plays a better role in the treatment of leukemia.